A Phase III trial assessing AstraZeneca’s lung cancer drug Tagrisso has met its primary endpoint in showing superior progression-free survival compared to standard chemotherapy.
News
Boehringer links with Dundee Uni in PROTAC deal
Boehringer Ingelheim and Dundee University have joined forces to develop a novel class of medicines that target disease causing proteins for degradation and address areas where there remains unmet need.
GSK licenses respiratory disease target from Five Prime
GSK has exercised its option for an exclusive license to a respiratory disease target identified through its research collaboration with Five Prime Therapeutics, triggering a $1.5 million milestone payment to the US biotech.
NHS spends £780,000 a day on antidepressants
The National Health Service in England is now shelling out £780,000 a day on antidepressants which, out of all BNF drug categories, saw the greatest numeric rise in prescriptions in 2015.
Wales confirms £80m treatment fund
A new £80 million fund designed to help accelerate access to treatments for patients with life-threatening illnesses in Wales has now been confirmed by the Welsh government.
NICE advises immediate referral for suspected childhood diabetes
The National Institute for Health and Care Excellence is advising that children and young people with suspected diabetes be seen by a specialist immediately.
BI, Lilly hook up to test breast cancer combo
Boehringer Ingelheim and Lilly are teaming up again, this time to test the potent of a novel combination of two medicines for the treatment of breast cancer.
UK officials reject calls to expand men B vaccination
Campaigners for expanding the scope of routine meningitis B vaccination in the UK say they are disappointed with a decision that a programme in infants aged one to two is not feasible.
FDA advisors back Sandoz’ Enbrel biosimilar
Sandoz’ biosimilar of Amgen’s blockbuster Enbrel has taken a big leap towards US approval after winning unanimous support from regulatory advisors.
Sepsis as serious as heart attack, says NICE
UK healthcare workers have been told to treat patients with suspected sepsis with the same urgency as those with suspected heart attack, in new guidelines from the National Institute for Health and Care Excellence.
NICE to expand reach of RA drug Cimzia
NICE has published draft guidance recommending UCB Pharma’s TNF inhibitor Cimzia as an option for severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable.
HIV transmission risk slashed with antiretroviral therapy
Findings of the PARTNER study, the world’s largest study of people with HIV who have had condomless sex with their HIV-negative partners, lend further weight to the use of antiretroviral therapy as a means of preventing infection with the virus.
FDA expands use of Pfizer’s Prevnar
US regulators have expanded the scope of Pfizer’s pneumococcal vaccine Prevnar 13, allowing its use in adults aged 18 to 49 years of age.
Research groups unite to create bank of cancer models
Four research powerhouses have come together to launch an international project aiming to set up a large, globally accessible, bank of new cancer cell culture models for the research.
Amgen’s Humira biosimilar backed by FDA panel
A US Food and Drug Administration’s advisory committee is supporting the approval of Amgen’s biosimilar of AbbVie’s biologic Humira, the world second best-selling drug.
